Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Phospho-ERK levels as predictors for chemotherapy of rectal carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcriptome analysis in patients with temporal lobe epilepsy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progression. Results: CfDNA fluctuated during treatment with the highest levels before diagnostic surgery and at progression. An increase was seen in 3 out of 4 patients at the time of progression while no increase was seen in 3 out of 4 patients without progression. CfDNA levels could aid in 3 out of 3 questionable cases of pseudo-progression. Methods: Eight newly diagnosed GB patients were included. Blood samples were collected prior to diagnosis, before start and during oncologic treatment until progression. Seven patients received concurrent radiotherapy/Temozolomide with adjuvant Temozolomide with one of the patients included in a clinical trial with either immunotherapy or placebo as add-on. One patient received radiation alone. CfDNA concentration was determined for each blood sample. Conclusions: It was feasible to measure cfDNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind10
Udgave nummer43
Sider (fra-til)4397-4406
Antal sider10
ISSN1949-2553
DOI
StatusUdgivet - 8 jul. 2019

ID: 58390158